Day One Biopharmaceuticals Inc.

5 months ago · prnewswire.com

Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S . in pediatric low-grade glioma.

6 months ago · businesswire.com

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier. Under the terms of the proposed transaction, shareholders of Day One will receive $21.50 in cash for each share of Day One that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

7 months ago · prnewswire.com

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.

7 months ago · zacks.com

Day One's stock surges 66% after Servier agrees to acquire it for $21.50 per share in a $2.5B deal, adding brain tumor drug Ojemda and oncology pipeline assets.

7 months ago · fool.com

The S&P 500 (^GSPC 1.33%) fell 1.33% to 6,740.02, the Nasdaq Composite (^IXIC 1.59%) slid 1.59% to 22,387.68, and the Dow Jones Industrial Average (^DJI 0.95%) dropped 0.95% to 47,501.55 as a weak jobs report and surging oil reinforced risk-off sentiment.

7 months ago · newsfilecorp.com

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - March 6, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Day One Biopharmaceuticals, Inc. ("Day One" or the "Company") (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Servier for $21.50 per share in an all-cash transaction, representing a total equity value of approximately $2.5 billion. The investigation concerns whether the Day One Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.

7 months ago · prnewswire.com

MILWAUKEE, March 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Day One (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Servier. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

7 months ago · prnewswire.com

NEW YORK, March 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) related to its sale to Servier Pharmaceuticals LLC.

7 months ago · businesswire.com

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) to Servier for $21.50 per share in cash. Halper Sadeh encourages Day One shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Day One and its board of directors viola.

7 months ago · benzinga.com

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares are trading higher Friday after the company announced that Servier will acquire it for $21.50 per share in cash.